<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901901</url>
  </required_header>
  <id_info>
    <org_study_id>12917</org_study_id>
    <secondary_id>2008-006021-14</secondary_id>
    <nct_id>NCT00901901</nct_id>
  </id_info>
  <brief_title>Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma</brief_title>
  <acronym>SEARCH</acronym>
  <official_title>A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily
      and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib
      once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients
      who are candidates for potentially curative intervention (i.e. surgical resection or local
      ablation) are not eligible for this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      European quality of life scale (5 dimensions) (EQ-5D)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 21, 2009</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">April 17, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization of the first patient until 34 months or date of death of any cause whichever came first</time_frame>
    <description>Overall Survival (OS) was defined as the time from date of randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Radiological Tumor Progression (TTP)</measure>
    <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
    <description>TTP was the time from randomization to radiological tumor progression. Participants without radiological tumor progression at the time of analysis were censored at their last date of tumor evaluation. Progressive disease (PD) was defined using Response Evaluation Criteria in Solid Tumors (RECIST version 1.0), as at least a 20% increase in the sum of longest diameter (LD) of measured lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions. Appearance of new lesions also constituted PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
    <description>Disease control was defined as the number of participants who had a best response rating of complet response (CR), partial response (PR), or stable disease (SD) according to RECIST assessed by magnetic resonance imaging (MRI) that was confirmed at least 28 days from the first demonstration of that rating. CR: disappearance of all clinical and radiological evidence of target and non-target tumors. PR: at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. SD: steady state of disease. Neither sufficient shrinkage for PR nor sufficient increase for PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index</measure>
    <time_frame>The EQ-5D was administered at the beginning of the visit prior to seeing the investigator. Questionnaires were to be completed every 6 weeks (Day 1 of each cycle) for subsequent cycles and at the end of treatment visit.</time_frame>
    <description>The European quality of life scale (5 dimensions) (EQ-5D) questionnaire was given to the participants at each visit. The EQ-5D questionnaire consisted of 5 ordinal categorical responses (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The scores for the EQ-5D dimensions are assigned according to the level of problems reported (1 'no problems'; 2 'some problems'; 3 'extreme problems'). The 5 health dimensions are summarized into a single score, the EQ-5D index score. The EQ-5D index score has a range of 0 and 1 with 0 representing death and 1 representing perfect health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS</measure>
    <time_frame>The EQ-5D VAS was administered at the beginning of the visit prior to seeing the investigator. Questionnaires were to be completed every 6 weeks (Day 1 of each cycle) for subsequent cycles and at the end of treatment visit.</time_frame>
    <description>Participants indicated on a scale of 0 (worst) to 100 (best) how good or bad their health state was on that particular day.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
    <description>Duration of response - RECIST: number of days from the date that CR or PR is first documented to date that PD is first objectively documented or to death before progression. Note: the relevant date is that of the first documentation, not the confirmation date (if participant progressed or died then censored=no) or to last observation if participant did not progress or die then censored=yes note: this last observation date should be the same as that used for time to progression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Response</measure>
    <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
    <description>Time to response was the number of days from randomization to the date the CR or PR was documented (with confirmation) (Note: the relevant date is that of the first documentation, not the confirmation date).</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor Response</measure>
    <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
    <description>Tumor response was the proportion of participants with the best tumor response (ie, achieving either a confirmed complete response [CR] or partial response [PR], according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">732</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006) + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006)</intervention_name>
    <description>Sorafenib 400 mg twice daily + matching erlotinib placebo daily</description>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva</intervention_name>
    <description>Sorafenib 400 mg twice daily + erlotinib 150 mg daily</description>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006) + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years of age

          -  Patients who have a life expectancy of at least 12 weeks

          -  Patients with histological or cytologically documented HCC

          -  Patients must have at least one tumor lesion that meets both of the following
             criteria:

               -  The lesion can be accurately measured in at least one dimension according to
                  response evaluation criteria in solid tumors (RECIST)

               -  The lesion has not been previously treated with local therapy

          -  Patients who have an ECOG PS (Eastern Cooperative Oncology Group Performance Status)
             of 0 or 1

          -  Cirrhotic status of Child-Pugh class A.

          -  Patients who give written informed consent prior to any study specific screening
             procedures with the understanding that the patient has the right to withdraw from the
             study at any time.

        Exclusion Criteria:

          -  History of cardiac disease: congestive heart failure &gt; New York Heart Association
             (NYHA) class 2; active coronary artery disease (CAD); cardiac arrhythmias requiring
             anti-arrhythmic therapy other than beta blockers or digoxin), or uncontrolled
             hypertension. Myocardial infarction more than 6 months prior to study entry is
             permitted.

          -  Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sogren's
             syndrome) including congenital abnormality (e.g. Fuch's dystrophy), abnormal slit-lamp
             examination using a vital dye (e.g. fluorescein, Bengal-Rose), and/or an abnormal
             corneal sensitivity test (Schirmer test or similar tear production test).

          -  History of interstitial lung disease (ILD).

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Previous treatment with yttrium-90 spheres

          -  Any condition that is unstable or which could jeopardize the safety of the patient and
             his/her compliance in the study.

          -  Uncontrolled ascites (defined as not easily controlled with diuretic treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153-5585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30110-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05651-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>7601003</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>838-0455</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larissa</city>
        <zip>41100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zrifin</city>
        <zip>6093000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggido</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington South</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>LIMA 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <zip>LIMA 34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <zip>656049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2009</study_first_posted>
  <results_first_submitted>April 10, 2013</results_first_submitted>
  <results_first_submitted_qc>September 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2013</results_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorafenib (Nexavar)</keyword>
  <keyword>Erlotinib (Tarceva)</keyword>
  <keyword>First Line</keyword>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 128 study centers in 26 countries in North America, South America, Europe, Africa, and Asia.</recruitment_details>
      <pre_assignment_details>Of the 962 screened participants, 242 were screen failures and were excluded from participated in the study. A total of 720 participants were randomized to study arms: 358 participants in the sorafenib + placebo group and 362 participants in the sorafenib + erlotinib group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)</title>
          <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
        </group>
        <group group_id="P2">
          <title>Sorafenib (Nexavar, BAY43-9006) + Placebo</title>
          <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="355"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205">19 of these participants are ongoing</participants>
                <participants group_id="P2" count="190">17 of these participants are ongoing</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="168"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study medication</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="324"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76">These participants are ongoing.</participants>
                <participants group_id="P2" count="65">These participants are ongoing.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="259"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol driven decision point</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)</title>
          <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
        </group>
        <group group_id="B2">
          <title>Sorafenib (Nexavar, BAY43-9006) + Placebo</title>
          <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="362"/>
            <count group_id="B2" value="358"/>
            <count group_id="B3" value="720"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="11.8"/>
                    <measurement group_id="B2" value="59.5" spread="13.0"/>
                    <measurement group_id="B3" value="59.9" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>non-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>former smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG stratification group</title>
          <description>Eastern Cooperative Oncology Group (ECOG) grade 0 = fully active; grade 1 = restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Macroscopic vascular invasion</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extrahepatic spread</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall Survival (OS) was defined as the time from date of randomization to death due to any cause.</description>
        <time_frame>From randomization of the first patient until 34 months or date of death of any cause whichever came first</time_frame>
        <population>The full analysis set (FAS), which was defined as all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Nexavar, BAY43-9006) + Placebo</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival (OS) was defined as the time from date of randomization to death due to any cause.</description>
          <population>The full analysis set (FAS), which was defined as all randomized participants</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289" lower_limit="250" upper_limit="321"/>
                    <measurement group_id="O2" value="259" lower_limit="226" upper_limit="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Radiological Tumor Progression (TTP)</title>
        <description>TTP was the time from randomization to radiological tumor progression. Participants without radiological tumor progression at the time of analysis were censored at their last date of tumor evaluation. Progressive disease (PD) was defined using Response Evaluation Criteria in Solid Tumors (RECIST version 1.0), as at least a 20% increase in the sum of longest diameter (LD) of measured lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions. Appearance of new lesions also constituted PD.</description>
        <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
        <population>The full analysis set (FAS), which was defined as all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva)</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Placebo</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Radiological Tumor Progression (TTP)</title>
          <description>TTP was the time from randomization to radiological tumor progression. Participants without radiological tumor progression at the time of analysis were censored at their last date of tumor evaluation. Progressive disease (PD) was defined using Response Evaluation Criteria in Solid Tumors (RECIST version 1.0), as at least a 20% increase in the sum of longest diameter (LD) of measured lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions. Appearance of new lesions also constituted PD.</description>
          <population>The full analysis set (FAS), which was defined as all randomized participants</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="82" upper_limit="126"/>
                    <measurement group_id="O2" value="122" lower_limit="88" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control</title>
        <description>Disease control was defined as the number of participants who had a best response rating of complet response (CR), partial response (PR), or stable disease (SD) according to RECIST assessed by magnetic resonance imaging (MRI) that was confirmed at least 28 days from the first demonstration of that rating. CR: disappearance of all clinical and radiological evidence of target and non-target tumors. PR: at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. SD: steady state of disease. Neither sufficient shrinkage for PR nor sufficient increase for PD.</description>
        <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
        <population>The full analysis set (FAS), which was defined as all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva)</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Placebo</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control</title>
          <description>Disease control was defined as the number of participants who had a best response rating of complet response (CR), partial response (PR), or stable disease (SD) according to RECIST assessed by magnetic resonance imaging (MRI) that was confirmed at least 28 days from the first demonstration of that rating. CR: disappearance of all clinical and radiological evidence of target and non-target tumors. PR: at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. SD: steady state of disease. Neither sufficient shrinkage for PR nor sufficient increase for PD.</description>
          <population>The full analysis set (FAS), which was defined as all randomized participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index</title>
        <description>The European quality of life scale (5 dimensions) (EQ-5D) questionnaire was given to the participants at each visit. The EQ-5D questionnaire consisted of 5 ordinal categorical responses (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The scores for the EQ-5D dimensions are assigned according to the level of problems reported (1 ‘no problems’; 2 ‘some problems’; 3 ‘extreme problems’). The 5 health dimensions are summarized into a single score, the EQ-5D index score. The EQ-5D index score has a range of 0 and 1 with 0 representing death and 1 representing perfect health.</description>
        <time_frame>The EQ-5D was administered at the beginning of the visit prior to seeing the investigator. Questionnaires were to be completed every 6 weeks (Day 1 of each cycle) for subsequent cycles and at the end of treatment visit.</time_frame>
        <population>The full analysis set (FAS), which was defined as all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva)</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Placebo</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index</title>
          <description>The European quality of life scale (5 dimensions) (EQ-5D) questionnaire was given to the participants at each visit. The EQ-5D questionnaire consisted of 5 ordinal categorical responses (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The scores for the EQ-5D dimensions are assigned according to the level of problems reported (1 ‘no problems’; 2 ‘some problems’; 3 ‘extreme problems’). The 5 health dimensions are summarized into a single score, the EQ-5D index score. The EQ-5D index score has a range of 0 and 1 with 0 representing death and 1 representing perfect health.</description>
          <population>The full analysis set (FAS), which was defined as all randomized participants</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cycle1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.777" lower_limit="0.760" upper_limit="0.795"/>
                    <measurement group_id="O2" value="0.774" lower_limit="0.757" upper_limit="0.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.753" lower_limit="0.735" upper_limit="0.771"/>
                    <measurement group_id="O2" value="0.749" lower_limit="0.732" upper_limit="0.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.728" lower_limit="0.708" upper_limit="0.748"/>
                    <measurement group_id="O2" value="0.724" lower_limit="0.706" upper_limit="0.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.704" lower_limit="0.681" upper_limit="0.726"/>
                    <measurement group_id="O2" value="0.700" lower_limit="0.678" upper_limit="0.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.679" lower_limit="0.653" upper_limit="0.705"/>
                    <measurement group_id="O2" value="0.675" lower_limit="0.650" upper_limit="0.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654" lower_limit="0.625" upper_limit="0.684"/>
                    <measurement group_id="O2" value="0.651" lower_limit="0.622" upper_limit="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS</title>
        <description>Participants indicated on a scale of 0 (worst) to 100 (best) how good or bad their health state was on that particular day.</description>
        <time_frame>The EQ-5D VAS was administered at the beginning of the visit prior to seeing the investigator. Questionnaires were to be completed every 6 weeks (Day 1 of each cycle) for subsequent cycles and at the end of treatment visit.</time_frame>
        <population>The full analysis set (FAS), which was defined as all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva)</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Placebo</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS</title>
          <description>Participants indicated on a scale of 0 (worst) to 100 (best) how good or bad their health state was on that particular day.</description>
          <population>The full analysis set (FAS), which was defined as all randomized participants</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cycle1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.397" lower_limit="73.219" upper_limit="75.576"/>
                    <measurement group_id="O2" value="74.656" lower_limit="73.504" upper_limit="75.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.649" lower_limit="71.420" upper_limit="73.877"/>
                    <measurement group_id="O2" value="72.907" lower_limit="71.735" upper_limit="74.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.900" lower_limit="69.518" upper_limit="72.281"/>
                    <measurement group_id="O2" value="71.158" lower_limit="69.854" upper_limit="72.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.151" lower_limit="67.542" upper_limit="70.759"/>
                    <measurement group_id="O2" value="69.409" lower_limit="67.891" upper_limit="70.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.402" lower_limit="65.520" upper_limit="69.283"/>
                    <measurement group_id="O2" value="67.660" lower_limit="65.875" upper_limit="69.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.653" lower_limit="63.468" upper_limit="67.837"/>
                    <measurement group_id="O2" value="65.911" lower_limit="63.827" upper_limit="67.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Duration of Response</title>
        <description>Duration of response - RECIST: number of days from the date that CR or PR is first documented to date that PD is first objectively documented or to death before progression. Note: the relevant date is that of the first documentation, not the confirmation date (if participant progressed or died then censored=no) or to last observation if participant did not progress or die then censored=yes note: this last observation date should be the same as that used for time to progression.</description>
        <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
        <population>The full analysis set (FAS), which was defined as all randomized participants. Duration of response was evaluated in the 14 participants in the sorafenib + placebo group and 24 participants in the sorafenib + erlotinib group who achieved their confirmed best response as CR or PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva)</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Placebo</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response - RECIST: number of days from the date that CR or PR is first documented to date that PD is first objectively documented or to death before progression. Note: the relevant date is that of the first documentation, not the confirmation date (if participant progressed or died then censored=no) or to last observation if participant did not progress or die then censored=yes note: this last observation date should be the same as that used for time to progression.</description>
          <population>The full analysis set (FAS), which was defined as all randomized participants. Duration of response was evaluated in the 14 participants in the sorafenib + placebo group and 24 participants in the sorafenib + erlotinib group who achieved their confirmed best response as CR or PR.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297" lower_limit="100" upper_limit="427"/>
                    <measurement group_id="O2" value="168" lower_limit="90">upper bound of the confidence interval is not available due to censored data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Response</title>
        <description>Time to response was the number of days from randomization to the date the CR or PR was documented (with confirmation) (Note: the relevant date is that of the first documentation, not the confirmation date).</description>
        <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
        <population>The full analysis set (FAS), which was defined as all randomized participants. Time to response was evaluated in the 14 participants in the sorafenib + placebo group and 24 participants in the sorafenib + erlotinib group who achieved their confirmed best response as CR or PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva)</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Placebo</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time to response was the number of days from randomization to the date the CR or PR was documented (with confirmation) (Note: the relevant date is that of the first documentation, not the confirmation date).</description>
          <population>The full analysis set (FAS), which was defined as all randomized participants. Time to response was evaluated in the 14 participants in the sorafenib + placebo group and 24 participants in the sorafenib + erlotinib group who achieved their confirmed best response as CR or PR.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="47" upper_limit="122"/>
                    <measurement group_id="O2" value="83.5" lower_limit="39" upper_limit="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tumor Response</title>
        <description>Tumor response was the proportion of participants with the best tumor response (ie, achieving either a confirmed complete response [CR] or partial response [PR], according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria).</description>
        <time_frame>From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks</time_frame>
        <population>The full analysis set (FAS), which was defined as all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva)</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib (Nexavar, BAY 43-9006) + Placebo</title>
            <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>Tumor response was the proportion of participants with the best tumor response (ie, achieving either a confirmed complete response [CR] or partial response [PR], according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria).</description>
          <population>The full analysis set (FAS), which was defined as all randomized participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>ALT: alanine transaminase; AST: aspartate transaminase; CPK: creatine phosphokinase; GI: gastrointestinal; INR: international normalized ratio</desc>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)</title>
          <description>Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)</description>
        </group>
        <group group_id="E2">
          <title>Sorafenib (Nexavar, BAY43-9006) + Placebo</title>
          <description>Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE v.3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac general - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Conduction abnormality, asystole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia, Bigeminy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ocular - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Anus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam), Large bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Necrosis, GI, Colon/Cecum/Appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Gallbladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Stricture, GI, Biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>No code in CTCAE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Chest/Thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Extremity - limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Scrotum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hepatobiliary - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection (Documented clinically), Biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection (Documented clinically), Bladder (urinary)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection (Documented clinically), Blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection (Documented clinically), Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection (Documented clinically), Peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Blood</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Catheter-related</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Heart (Endocarditis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Penis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Cornea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Viral hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intraop injury, Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bilirubin (Hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>CPK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Muscle weakness, Extremity - lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Muscle weakness, Whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy (possibly related to cancer treatment)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mood Alteration, Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mood alteration, Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Neuropathy: Cranial, CN V Motor-jaw muscles; Sensory-facial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Syncope (Fainting)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (Shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, Bronchopulmonary NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, Nose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, Respiratory tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage with surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Anus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Lower GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Upper GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Varices (Esophageal)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Varices (rectal)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU, Urinary NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Peripheral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Thrombosis/Embolism (vascular access)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Thrombosis/Thrombus/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTCAE v.3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="355" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="349" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="272" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Distension</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Chest/Thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Extremity - limb</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Head/Headache</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Muscle</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bilirubin (Hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab - Other</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mood alteration, Depression</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dyspnea (Shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage pulmonary, Nose</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI must send a draft manuscript of the publication or abstract to the sponsor 30 days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trial-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

